A Feasibility Study of Internet Delivered Prolonged Exposure

December 6, 2023 updated by: Maria Bragesjo, Karolinska Institutet

A Feasibility Study of Internet Delivered Prolonged Exposure for Patients Wit Post-traumatic Stress Disorder

The primary objective with this study is to investigate the feasibility and acceptability of ten weeks of internet delivered prolonged exposure delivered through a digital platform with therapist support. The secondary objective is to investigate preliminary effects of internet delivered prolonged exposure in terms of reducing symptoms of post-traumatic stress, depression and increase quality of life.

Study Overview

Status

Completed

Detailed Description

The investigators will investigate internet delivered prolonged exposure delivered as a ten-week treatment comprising of six modules (psychoeducation/rational, in vivo exposure, imaginal exposure, common problems during exposure, hot spots and relapse prevention). The feasibility and acceptability and preliminary effects of treatment- and assessment procedures will be evaluated using a within-group design with repeated measurements and qualitative interviews. Recruitment is designed to be broadly inclusive with minimal exclusion criteria. Patients will be recruited from a psychiatric clinic specialized in PTSD in Stockholm, Sweden and by advertisements in newspapers and social media.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Stockholm, Sweden
        • Traumaprogrammet, Psykiatri Sydväst

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Currently primary diagnosis PTSD according to DSM-5 diagnostic criteria for PTSD
  • ≥ 18 years
  • Fluent in Swedish
  • Signed informed consent

Exclusion Criteria:

  • PTSD is not the primary concern
  • Initiation or adjustment of any psychotropic medication within the last 4 weeks prior to commencement of treatment
  • Ongoing substance dependence
  • Current suicide risk meriting crisis intervention
  • Psychotic disorder
  • Ongoing trauma-focused psychological treatment
  • Ongoing trauma-related threat (e.g. living with a violent spouse)

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Internet delivered prolonged exposure
Internet delivered prolonged exposure for ten weeks with therapist support.
Internet delivered prolonged exposure for ten weeks with therapist support.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Number of imaginal exposures made by the participant during the treatment period
Time Frame: Through the treatment period, up to 10 weeks
Number of imaginal exposures made by the participant during the treatment
Through the treatment period, up to 10 weeks
Number of in vivo exposures made by the participant during the treatment period
Time Frame: Through the treatment period, up to 10 weeks
Number of in vivo exposures made by the participant during the treatment period
Through the treatment period, up to 10 weeks
The proportion of participants that conducts the weekly measures and further assessment points
Time Frame: Through study completion up to the 6 months follow up]
The proportion of participants that conducts the weekly measures and further assessment points
Through study completion up to the 6 months follow up]
The proportion of participants that go through the entire treatment period
Time Frame: Completion of the treatment period, ten weeks
The proportion of participants that go through the entire treatment period
Completion of the treatment period, ten weeks
Adverse events related to the treatment
Time Frame: Through study completion, up to the 6 months follow up
Treatment acceptability
Through study completion, up to the 6 months follow up
Number of drop-outs from treatment
Time Frame: Completion of the treatment period, up to 10 weeks
Treatment acceptability
Completion of the treatment period, up to 10 weeks
Participants experience/satisfaction with treatment and assessment procedures through qualitative interviews
Time Frame: Completion of the treatment period up to the 6-month follow up
Qualitative interviews
Completion of the treatment period up to the 6-month follow up
Participants satisfaction with treatment, assessed by The Client Satisfaction Questionnaire (CSQ-8).
Time Frame: Completion of the treatment period, up to 10 weeks
The CSQ-8 yields a single score measuring a single dimension of overall satisfaction. An "overall score" is calculated by summing the score on each of the eight scale item. Scores range from 8 to 32, with higher values indicating higher satisfaction.
Completion of the treatment period, up to 10 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in PTSD symptoms as assessed by the Clinician Administered PTSD Scale (CAPS-5)
Time Frame: Baseline, 1 month and 6 months follow up
The CAPS-5 is structured interview that assesses the Diagnostic and Statistical Manual of Mental Disorders version 5 (DSM-5) criteria for PTSD (Weathers et al., 2013). Each item is rated on a severity scale ranging from 0 (Absent) to 4 (Extreme/incapacitating) and combines information about frequency and intensity for each of the 20 symptoms. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.
Baseline, 1 month and 6 months follow up
Change in PTSD symptoms as assessed by the PTSD Check List - DSM-5 (PCL-5)
Time Frame: Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
The PCL-5 is a 20-item self-report measure based upon the Diagnostic and Statistical Manual (DSM-5) criteria for PTSD. Total Score (Range 0-80 with higher scores representing more PTSD symptoms.
Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in ICD-11 PTSD and complex PTSD symptoms as assessed by the International Trauma Questionnaire (ITQ).
Time Frame: Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
The ITQ includes six items measuring each PTSD symptom cluster and these items measure how bothersome each symptom has been in the past month. The ITQ also includes six items measuring each 'Disturbance in Self- Organization' (DSO) symptom in complex PTSD. These items measure how a respondent typically feels, thinks about oneself, and relates to others. The PTSD and DSO symptoms are accompanied by three items measuring associated functional impairments in the domains of social, occupation, and other important areas of life. All items are answered on a 5-point Likert scale ranging from 0 (Not at all) to 4 (Extremely). Thus, PTSD and DSO symptom scores range from 0 to 24 and CPTSD symptom scores range from 0 to 48. Higher scores represents more PTSD and complex PTSD symptoms.
Baseline, weekly through 10 weeks of treatment, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in depressive symptoms as measured by the Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
The PHQ-9 is a widely used and well-validated instrument for measuring the severity of depressive symptoms. Scores are calculated based on how frequently a person experiences 9 symptoms of depression ranging from "not at all" response is scored as 0; "several days" response is 1; "more than half the days" response is 2; and "nearly every day" response is 3. Higher scores represents more depressive symptoms.
Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in quality of life measured by Euroqol, EQ-5D
Time Frame: Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.
Change in overall health from baseline to post treatment and follow up . EQ-5D is a standardized self-report measure of overall health status measured in terms of five dimensions; mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Mobility dimension asks about the person's walking ability. Self-care dimension asks about the ability to wash or dress by oneself, and usual activities dimension measures performance in "work, study, housework, family or leisure activities". In pain/discomfort dimension, it asks how much pain or discomfort they have, and in anxiety/depression dimension, it asks how anxious or depressed they are. The respondents self-rate their level of severity for each dimension using a three-level scale: 1 having no problems, 2 having some problems and 3 having extreme problems. A higher score indicate worse severity.
Baseline, post-treatment (immediately after treatment completion at 10 weeks), and the 1 month and 6 months follow up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Collaborators

Investigators

  • Principal Investigator: Maria Bragesjö, PhD, Karolinska Institutet

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 18, 2022

Primary Completion (Actual)

September 9, 2023

Study Completion (Actual)

September 9, 2023

Study Registration Dates

First Submitted

September 23, 2022

First Submitted That Met QC Criteria

September 27, 2022

First Posted (Actual)

September 29, 2022

Study Record Updates

Last Update Posted (Estimated)

December 7, 2023

Last Update Submitted That Met QC Criteria

December 6, 2023

Last Verified

December 1, 2023

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Post Traumatic Stress Disorder

Clinical Trials on Internet delivered prolonged exposure

Subscribe